-$1.08 EPS Expected for Odonate Therapeutics Inc (NASDAQ:ODT) This Quarter

Equities analysts expect Odonate Therapeutics Inc (NASDAQ:ODT) to report ($1.08) earnings per share (EPS) for the current fiscal quarter, according to Zacks. Zero analysts have provided estimates for Odonate Therapeutics’ earnings, with the lowest EPS estimate coming in at ($1.14) and the highest estimate coming in at ($1.01). Odonate Therapeutics reported earnings of ($1.17) per share during the same quarter last year, which would indicate a positive year over year growth rate of 7.7%. The business is expected to issue its next earnings report on Friday, February 28th.

On average, analysts expect that Odonate Therapeutics will report full year earnings of ($4.23) per share for the current fiscal year, with EPS estimates ranging from ($4.30) to ($4.16). For the next year, analysts expect that the firm will post earnings of ($4.73) per share, with EPS estimates ranging from ($5.21) to ($4.25). Zacks’ earnings per share averages are a mean average based on a survey of sell-side analysts that follow Odonate Therapeutics.

Get Odonate Therapeutics alerts:

Several equities analysts have issued reports on the company. ValuEngine lowered Odonate Therapeutics from a “hold” rating to a “sell” rating in a research note on Wednesday, October 2nd. Zacks Investment Research lowered Odonate Therapeutics from a “buy” rating to a “hold” rating in a research note on Tuesday.

Large investors have recently modified their holdings of the company. Meeder Asset Management Inc. raised its position in shares of Odonate Therapeutics by 198.7% during the second quarter. Meeder Asset Management Inc. now owns 1,574 shares of the company’s stock worth $57,000 after purchasing an additional 1,047 shares during the period. Tower Research Capital LLC TRC raised its position in shares of Odonate Therapeutics by 106.9% during the second quarter. Tower Research Capital LLC TRC now owns 1,703 shares of the company’s stock worth $63,000 after purchasing an additional 880 shares during the period. Russell Investments Group Ltd. raised its position in shares of Odonate Therapeutics by 109.8% during the second quarter. Russell Investments Group Ltd. now owns 5,351 shares of the company’s stock worth $196,000 after purchasing an additional 2,800 shares during the period. Rhumbline Advisers raised its position in shares of Odonate Therapeutics by 30.0% during the third quarter. Rhumbline Advisers now owns 12,365 shares of the company’s stock worth $322,000 after purchasing an additional 2,854 shares during the period. Finally, Swiss National Bank acquired a new position in shares of Odonate Therapeutics during the second quarter worth approximately $455,000. 96.64% of the stock is currently owned by institutional investors.

ODT traded up $0.97 during trading on Tuesday, hitting $33.10. The company’s stock had a trading volume of 98,400 shares, compared to its average volume of 91,828. Odonate Therapeutics has a twelve month low of $11.54 and a twelve month high of $43.75. The stock’s fifty day moving average price is $29.10 and its 200-day moving average price is $29.57. The firm has a market capitalization of $1.03 billion, a P/E ratio of -9.09 and a beta of 1.83.

Odonate Therapeutics Company Profile

Odonate Therapeutics, Inc, a pharmaceutical company, develops therapeutics for the treatment of cancer. It is developing tesetaxel, an orally administered chemotherapy agent, which is in Phase III clinical study for patients with locally advanced or metastatic breast cancer. The company was founded in 2013 and is based in San Diego, California.

Featured Story: Understanding the two types of arbitrage

Get a free copy of the Zacks research report on Odonate Therapeutics (ODT)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Receive News & Ratings for Odonate Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Odonate Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.